PPPreetesh Kumar Panda

Preetesh Kumar Panda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Preetesh Kumar Panda has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Sudhir Kumar Paidesetty

    Medicinal Chemistry Research Laboratory, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan Deemed to be University, Bhubaneswar 751003, Odisha, India

    5 shared publications
  • Suvadeep Mal

    Medicinal Chemistry Research Laboratory, School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan (Deemed to be University), Bhubaneswar, Odisha 751003, India

    4 shared publications
  • Monalisa Mahapatra

    School of Pharmacy and Life Sciences, Centurion University of technology and management, Bhubaneswar, Odisha, 752050, India

    3 shared publications
  • Ajit Kumar Bishoyi

    Central Research Laboratory, IMS and SUM Hospital, Siksha ‘O’ Anusandhan (Deemed to be University), Bhubaneswar, Odisha, 751003, India

    2 shared publications
  • Kakarla Pakeeraiah

    Medicinal Chemistry Research Laboratory, School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan (Deemed to be University), Bhubaneswar, Odisha 751003, India

    2 shared publications
  • Kakarla Pakeeraiah

    Medicinal Chemistry Research Laboratory School of Pharmaceutical Sciences Siksha ‘O’ Anusandhan Bhubaneswar Odisha 751003 India

    2 shared publications

Latest Publications

  • Open Access

    Folate-directed morin nano-gold decorated with chitosan: a multifunctional arsenal against triple-negative breast cancer and AMR superbugs

    by Suvadeep Mal, Thakur Gurjeet Singh, Ajit Kumar Bishoyi, Kakarla Pakeeraiah, Preetesh Kumar Panda, Monalisa Mahapatra, Suvadra Das, Roshan Kumar, Sudhir Kumar Paidesetty, Partha Roy

    Chitosan and folic acid dual-functionalized morin-reduced gold nanosystems exhibit multifunctionalities to tackle critical clinical challenges, like triple-negative breast cancer and antimicrobial resistance.

  • Open Access

    The State of Imidazolone as an Evolving Pharmacophore: Current Progress and Clinical Significance in Oncology and AMR

    by Preetesh Kumar Panda, Suvadeep Mal, Monalisa Mahapatra, Aruna Ghose, Sudhir Kumar Paidesetty

    Nitrogen-bearing heterocycles have been fundamental scaffolds in drug discovery, contributing significantly to the design and development of therapeutic agents since the inception of modern medicinal chemistry. Among them, imidazolones have shown notable therapeutic relevance, particularly in oncology, antimicrobial resistance (AMR), and inflammation, yet they remain relatively underexplored. Nevertheless, the significant therapeutic and clinical efficacy of imidazolone-bearing drugs, such as Nilutamide, Irbesartan, and Leucettinib-21, in anticancer, antihypertensive, and neurotherapeutic applications has stimulated increasing interest in imidazolone chemistry and its medicinal potential. This review systematically discusses the major synthetic strategies, structure–activity relationships, and mechanistic principles governing the biological activity of imidazolones. Particular emphasis is placed on their rapidly expanding role as anticancer agents targeting enzymes and signaling proteins such as carbonic anhydrases, epidermal growth factor receptors (EGFR), Bcl-2 protein family, and checkpoint kinases, along with their potential applications in antimicrobial and anti-inflammatory therapies. Furthermore, the review highlights the complementary roles of computational modeling and biological evaluation in understanding the interactions of imidazolone-bearing compounds with various microbial and cancer-related receptors. These integrated studies reveal their ability to engage multiple biological targets and validate their observed pharmacological activities. The convergence of in silico predictions with experimental findings offers valuable guidance for the rational development of imidazolone-based therapeutics. Overall, this review emphasizes imidazolones as promising scaffolds with significant potential for future drug discovery and development.


  • Open Access

    Design, synthesis and computational approach of vanillyl–imidazolidinyl–sulfamethoxazole derivatives as potent antimicrobial candidates tackling microbial resistance

    by Preetesh Kumar Panda, Kakarla Pakeeraiah, Suvadeep Mal, Monalisa Mahapatra, Ajit Kumar Bishoyi, Sudhir Kumar Paidesetty

    Potent vanillyl–imidazolidinyl–sulfamethoxazole derivatives were designed and synthesized among which compounds 4d and 4g have shown significant results combating against MDR pathogens.


  • In Silico Investigation and MD Simulation Approaches of Newly Designed Quercetin–Imidazole Analogs for Anticancer and Antifungal Efficacy

    by Monalisa Mahapatra, Rohit Pritam Das, Kakarla Pakeeraiah, Suvadeep Mal, Preetesh Kumar Panda, Suman Kumar Mekap, Sudhir Kumar Paidesetty

    Molecules with potency and low toxicity are the leading army in the battlefield of multidrug resistance. Quercetin is found in abundance in the nature as a potent flavonoid and bears the tag of flavonoid paradox due to the poor bioavailability, however, it still possess distinct systemic actions, and this marks curiosity in the research field. The present study elaborates targeted in silico and simulation approaches of newly designed quercetin analogs toward their anticancer and antifungal properties by screening against human epidermal growth factor receptor and lanosterol C14‐alpha demethylase receptors. The molecules were investigated pharmacokinetically via drug‐likeness, toxicity prediction (lethal dose, LD 50 ), PASS prediction, molecular docking, molecular dynamics simulation, and their quantum mechanics have been measured using molecular orbital calculations through highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) calculations. The prediction from P a > P i scores displayed its potential for squalene epoxide inhibitors, antimycobacterial, and antineoplastic activities and also showed prospectively better molecular docking scores against the selected targeted enzymes. Among the series, QIz II stood out as a compelling inhibitor; showcasing highest binding affinity with fungal protein by impressive docking score of −10.7 kcal/mol. Compound QIz XX demonstrated the highest binding affinity of −9.31 kcal/mol with the anticancer protein.


  • Open Access

    Multimodal antibacterial potency of newly designed and synthesized Schiff's/Mannich based coumarin derivatives: potential inhibitors of bacterial DNA gyrase and biofilm production

    by Kakarla Pakeeraiah, Pragyan Paramita Swain, Alaka Sahoo, Preetesh Kumar Panda, Monalisa Mahapatra, Suvadeep Mal, Rajesh Kumar Sahoo, Pratap Kumar Sahu, Sudhir Kumar Paidesetty

    The briskened urge to develop potential antibacterial candidates against multidrug-resistant pathogens has motivated the present research study. Herein, newly synthesized coumarin derivatives with azomethine and amino-methylated as the functional groups have been focused on their antibacterial efficacy. The study proposed two distinct series: 3-acetyl substituted coumarin derivatives, followed by the Schiff base approach (5a–5i), and formaldehyde-secondary cyclic amine-based derivatives (7a–7g), using the Mannich base approach, further the compounds have been confirmed through various spectral studies. Further, target-specific binding affinity has been affirmed via in silico study. In vitro antibacterial study suggested compounds 5d and 5f to be most effective against S. aureus and multidrug-resistant K. pneumoniae, with MIC values of 8 and 16 μg mL−1. Among them, the compounds 5d and 5f showed excellent binding scores against different bacterial gyrase compared to the standard novobiocin. Based on RMRS, RMSF, Rg, and H-bond plots, MD simulation study at 100 ns also suggested better stability of 5d inside gyraseB of E. coli than the complex of E. coli-GyrB-novobiocin. The toxicity and pharmacokinetic profiles showed favorable drug-likeness. Overall, systematic in vitro and in silico assessment suggested that multimodal antibacterial derivatives 5d and 5f strongly inhibit both bacterial DNA gyrase and biofilm formation of drug-resistant pathogens, suggesting their potency in mainstream antibacterial therapy.